What is 5-Amino-1MQ? What's been measured

Reviewed 15 sourcesPublished by PepVault

5-Amino-1MQ is a small molecule that blocks the NNMT enzyme. What mouse and cell studies measured on fat, muscle and liver, and why no human data exists.

A woman in a coral top dropping blueberries into a glass blender jar, kiwi on a board beside her
Last reviewed
Sources
15
Questions
10
Compounds
2

The short answer

5-Amino-1MQ is a small molecule, not a peptide, that blocks NNMT, an enzyme that runs high in the fat of obese mice. Every result so far comes from mice, rats and cells: in obese mice, daily injections cut body weight and fat without lowering food intake. No human study has been published, and ClinicalTrials.gov lists no registered trial.

Every number checked at its primary source · · 15 sources · How we research

Evidence: Animal and cell studies only: no published human study and no registered trial as of November 2026.

A woman in a coral top dropping blueberries into a glass blender jar, kiwi on a board beside her

Has 5-Amino-1MQ been tested in people?

No. Every published result for 5-Amino-1MQ comes from mice, rats or cells grown in a dish. A search of ClinicalTrials.gov in November 2026 for "5-amino-1MQ", "5-amino-1-methylquinolinium" and "NNMT inhibitor" returned no registered trial of it12, and PubMed lists no human study. Drugs@FDA has no application for it, so it has no FDA-approved form13.

That shapes everything below. A mouse result tells you what the molecule did in a mouse, at a dose given by injection, over days to weeks. It is a reason to run a human trial, and it is not yet a result in people.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs an oral compound like 5-Amino-1MQ as a daily dose with a reminder, and keeps your weigh-ins and waist on the same timeline, so you can see whether anything moved and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What is 5-Amino-1MQ, and is it a peptide?

It is not a peptide. A peptide is a chain of amino acids; 5-Amino-1MQ is a small ring-shaped molecule, a quinoline ring carrying a methyl group and an amino group, which is what its full name, 5-amino-1-methylquinolinium, spells out8. Its charged form weighs about 159 daltons6. It sits on peptide sites because people run it beside GLP-1s and other metabolic peptides.

It came out of a drug-discovery program at the University of Texas Medical Branch in Galveston. In 2017 the team screened families of small molecules against the NNMT enzyme and found the methylquinoliniums worked best, blocking it at about 1 micromolar in a test tube8. 5-Amino-1MQ was the one they took into animals1.

What does NNMT do in fat cells?

NNMT (nicotinamide N-methyltransferase) is an enzyme that tags vitamin B3, in its nicotinamide form, with a methyl group. Each tag uses up a molecule of SAM, the cell's main methyl donor, and takes the nicotinamide away from the recycling route that rebuilds NAD+, a molecule cells need to turn food into energy7.

The interest started with a 2014 Nature paper from Harvard. NNMT levels were raised in the fat and liver of obese and diabetic mice, and when the team switched the gene down in those tissues, the mice burned more energy and were protected from diet-induced obesity7. Blocking NNMT raised SAM and NAD+ in fat tissue7.

A fork diagram: nicotinamide either goes to NNMT, which spends one SAM and makes 1-MNA, or to the recycling route that rebuilds NAD+; 5-amino-1MQ blocks the NNMT arm
Look at the fork: block NNMT, and nicotinamide and SAM stay in the cell, which is why NAD+ and SAM rose in treated fat cells.

5-Amino-1MQ does the same job with a drug instead of a gene switch. In cultured mouse fat cells it cut the enzyme's product, raised NAD+ about 1.2 to 1.6-fold, raised SAM, and at 30 and 60 micromolar cut new fat production by 50% and 70%1. It left related enzymes alone, including the NAD+ recycling enzymes and SIRT11.

What happened to the obese mice?

In the first animal study, obese mice on a high-fat diet got 5-Amino-1MQ by injection under the skin three times a day for 11 days, nine mice per group. Treated mice lost about 5.1% of their body weight while untreated mice gained about 1.4%, and both groups ate about the same amount of food1. The main belly fat pad shrank by about 35%, fat cells were over 30% smaller, and total cholesterol was about 30% lower1.

The 2021 follow-up added a diet change. Obese mice switched to a lean diet lost about 29% of their fat mass with 5-Amino-1MQ, against about 3% on the diet switch alone, and their ratio of lean mass to body weight rose 6.4%2. Their body composition and liver fat ended up at the level of mice kept lean all along2.

A 2024 study ran four weeks of once-daily injections in obese mice that stayed on their high-fat diet. The higher dose held back weight and fat gain rather than reversing it, improved how the mice handled sugar and insulin, and reduced fatty liver: one type of fat build-up in the liver fell by 73% against controls3. Food intake and lean mass did not change3.

StudyAnimalsHow it was givenMain result
Neelakantan 20181Obese mice, high-fat diet, 9 per groupInjection three times a day, 11 days−5.1% body weight vs +1.4% in controls; same food intake
Sampson 20212Obese mice switched to a lean diet, 8 treatedDaily injectionAbout 29% fat-mass loss vs about 3% on diet alone
Babula 20243Obese mice, high-fat diet, 8 per groupDaily injection, about 4 weeksLess weight and fat gain; less fatty liver
Neelakantan 2019424-month-old mice, injured leg muscleInjection twice a day, 2 to 4 weeksAbout 70% more peak muscle force after injury
Dimet-Wiley 20245Aged female mice, with or without wheel runningDaily injection, 8 weeksGrip strength +40% alone, +60% with exercise
Body weight change at day 11 in obese mice: +1.4% untreated against −5.1% on 5-amino-1MQ, with the same food intake
Look at both pairs: weight moved apart while food eaten stayed about the same.

These are mouse results, and results in mice often don't carry over to people. Every study in the table gave 5-Amino-1MQ by injection, not by mouth.

Does it do anything for muscle?

NNMT also rises in muscle with age, and the same group tested whether blocking it helps old muscle repair itself. In 24-month-old mice, old for a mouse, with an injured leg muscle, 5-Amino-1MQ made muscle stem cells more active. The repaired fibers were nearly twice as large in cross-section, and the muscle's peak force was about 70% higher than in untreated mice4.

In 2024 aged female mice got eight weeks of daily injections, a weighted running wheel, or both. Grip strength rose about 40% on 5-Amino-1MQ alone, about 20% with exercise alone, and about 60% with both5. This, with the 2021 lean-mass result, is where the "keeps muscle on a cut" idea comes from, and both are animal results.

Does it work when swallowed?

This is the gap that matters most for how people take it. Human pharmacokinetics, how a body absorbs and clears a drug, have not been published. The two animal studies disagree on how much of an oral dose reaches the blood, its bioavailability:

SpeciesShare of an oral dose reaching the bloodHalf-life after an oral dose
Rats (Awosemo 2021)638.4%6.9 hours
Mice (Babula 2024)33.5%14.8 hours
Two bars for the share of an oral dose reaching the blood: 38.4% in rats against 3.5% in mice; every efficacy study used injection
Look at the gap between the bars: the two animal studies disagree ten-fold, and no human figure exists.

The mouse team put its low figure down to poor absorption from the gut and heavy breakdown in the liver, and it gave the drug by injection under the skin, which reached fat, muscle and liver well3. Community use is mostly by mouth, the route with the least data behind it. Its half-life, the time for blood levels to halve, also has no human figure.

Is 5-Amino-1MQ safe?

Nobody knows yet in people. In the mice, the researchers saw no observable adverse effects at the doses tested, and in a short dose-escalation test in two mice a total of 60 mg per kg a day was well tolerated1. In the 2021 study, repeated dosing over the seven-week study caused no adverse effects, and blood chemistry showed no sign of organ damage2.

One lab screen is worth knowing. Tested at 10 micromolar against a panel of receptors and enzymes, 5-Amino-1MQ hit only one other target, blocking monoamine oxidase A (MAO-A) by 67.4%3. MAO-A breaks down brain chemicals such as serotonin, and several medicines, including some antidepressants, act on the same system, so anyone taking one has a good question for a doctor or pharmacist.

NNMT also turns up in cancer research, where blocking it is studied as a way to slow tumors. 5-Amino-1MQ slowed the growth of HeLa cervical cancer cells in a dish while leaving kidney-derived HEK-293 cells largely untouched10, and in mice it slowed bladder tumors and helped an immunotherapy drug work11. Neither is a weight-loss result, and no person received it.

Commonly reported: little to feel from day to day. Only a handful of people on the open forums we read have written about it: a few describe more energy or endurance, or easier fat loss alongside a diet or a GLP-1, others notice nothing, and one person described a flushed face.

How does it compare with semaglutide?

People often run the two together, so the difference in evidence is worth seeing side by side. Semaglutide is a GLP-1 drug that quiets appetite; 5-Amino-1MQ, in mice, changed fat-cell metabolism without changing how much the animals ate1.

Measure5-Amino-1MQSemaglutide
What it isSmall molecule that blocks NNMTGLP-1 receptor agonist (a peptide)
Tested in peopleNo published study, no registered trial12Yes: 1,961 adults in STEP 114
Weight result−5.1% in 11 days, in obese mice1−14.9% at 68 weeks, against −2.4% on placebo14
AppetiteNo change in food intake, in mice1Activates GLP-1 receptors in brain areas that regulate appetite15
FDA statusNo approved product13Approved for long-term weight reduction, as Wegovy15

Who did the research?

Most of the obesity and muscle work comes from one group, the lab of S. J. Watowich at the University of Texas Medical Branch12345. Watowich founded Ridgeline Therapeutics, and H. Neelakantan, an author on every paper in the table, works there. The 2021 diet study, the 2022 gut-bacteria study and both 2024 papers declare that tie2359. The 2018 and 2019 papers, and the 2021 rat drug-level study that Watowich and Neelakantan co-wrote, declare no conflict146. A separate study from the same group found that the drug plus a low-fat diet gave obese mice their own gut-bacteria pattern9.

Company-linked research is normal at this stage. It also means the fat and muscle findings have not yet been repeated by an independent lab, even in animals; the outside labs that have used it so far studied cancer cells and tumors1011.

If you're tracking it, what's worth logging?

No human dose has been tested, so the range on our 5-Amino-1MQ Dose Guide page is a convention from community use, not a trial result. The mouse findings point to what would show up if anything does: body fat rather than appetite, and strength over weeks.

  • Weight and waist on the same day each week, since the mouse effect was on fat rather than on appetite.
  • A simple strength marker, such as grip or a working set you repeat.
  • Anything new you notice, with the date, including flushing or sleep changes.

PepVault logs an oral compound like 5-Amino-1MQ as a daily dose with a reminder, and keeps your weigh-ins and waist on the same timeline, so you can see whether anything moved and when. Log it in PepVault

Track it in the app

Sources

  1. Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PubMed 29155147
  2. Sampson CM et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep. 2021. PubMed 33707534
  3. Babula JJ et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. PubMed 39161060
  4. Neelakantan H et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019. PubMed 30753815
  5. Dimet-Wiley AL et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep. 2024. PubMed 38969654
  6. Awosemo O et al. Development and validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021. PubMed 34304009
  7. Kraus D et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PubMed 24717514
  8. Neelakantan H et al. Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. J Med Chem. 2017. PubMed 28548833
  9. Dimet-Wiley A et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022. PubMed 35013352
  10. Akar S et al. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells. J Obstet Gynaecol. 2021. PubMed 33645410
  11. Yang M et al. NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. J Immunother Cancer. 2024. PubMed 39067875
  12. ClinicalTrials.gov search for 5-amino-1MQ (no registered studies, searched November 2026). clinicaltrials.gov
  13. Drugs@FDA via openFDA: no application lists methylquinolinium as an active ingredient (searched November 2026). api.fda.gov
  14. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
  15. WEGOVY (semaglutide) prescribing information, DailyMed, Novo Nordisk, June 2026. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo